Alnylam Pharmaceuticals (ALNY) Net Income Growth (1y) (2010 - 2026)
Alnylam Pharmaceuticals (ALNY) Net Income Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 63.48% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 1,228.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,228.66% |
| Dec 31, 2025 | 233.17% |
| Sep 30, 2025 | 362.33% |
| Jun 30, 2025 | -292.43% |
| Mar 31, 2025 | 72.32% |
| Dec 31, 2024 | 39.24% |
| Sep 30, 2024 | -175.51% |
| Jun 30, 2024 | 93.88% |
| Mar 31, 2024 | 62.13% |
| Dec 31, 2023 | 33.55% |
| Sep 30, 2023 | 136.40% |
| Jun 30, 2023 | 0.50% |
| Mar 31, 2023 | 27.56% |
| Dec 31, 2022 | 19.72% |
| Sep 30, 2022 | -98.48% |
| Jun 30, 2022 | -46.34% |
| Mar 31, 2022 | -20.00% |
| Dec 31, 2021 | -6.13% |
| Sep 30, 2021 | 19.26% |
| Jun 30, 2021 | -5.76% |